The role of calcineurin inhibitors in the progression of hepatocellular carcinoma after liver transplantation

Introduction. Orthotopic liver transplantation is the most radical method of treatment of hepatocellular carcinoma. The high recurrence rate limits the use of transplantation in patients with hepatocellular cancer. Immunosuppressive therapy may affect the frequency of oncoprogression after liver transplantation
Aim. To evaluate the role of immunosuppressive therapy in the postoperative progression of hepatocellular cancer in patients after liver transplantation
Material and methods. The recurrence rate of hepatocellular cancer and tumor free survival in 104 patients after liver transplantation were analyzed. To evaluate the effect of the immunosuppression main component concentration on the postoperative progression of hepatocellular carcinoma, we studied the mean baseline concentration (C0) for the entire follow-up period for patients with a tumor-free period and the mean baseline concentration for patients with hepatocellular carcinoma progression, in whom only the duration of the tumor-free period was studied. According to the degree of tumor lesion, patients were distributed in accordance with the Milan criteria (based on the results of a pathologic and morphological examination of the recipient's explanted liver.
Results. The values of the baseline blood level of tacrolimus>6.0 ng/ml and cyclosporine A>100 ng/ml is associated with a high rate of progression of hepatocellular cancer. Reducing the load of calcineurin inhibitors can reduce the incidence of cancer progression by at least 2 times. The values of 1-, 3- and 5-year relapse-free survival in patients with advanced cancer and low figures of the baseline blood level of calcineurin inhibitor are 82%, 70% and 70%, respectively.
Conclusion. Minimization of immunosuppression is of crucial importance in the prevention of posttransplant progression of hepatocellular cancer, especially among patients with its common form.

1. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693–699. PMID: 8594428 https://doi.org/10.1056/NEJM199603143341104

2. Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A. OLT for HCC Consensus Group. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol. 2012;13(1):e11–e22. PMID: 22047762 https://doi.org/10.1016/S1470-2045(11)70175-9

3. Voskanyan SE, Naidenov EV, Artemiev AI, Kolyshev IYu, Zabezhinsky DA, Gubarev KK, et al. Long-term results of liver transplantation for hepatocellular cancer. Annaly khirurgicheskoy gepatologii = Annals of HPB Surgery. 2021;26(2):68–82. (In Russ.). https://doi.org/10.16931/10.16931/1995-5464.2021-2-68-82

4. Gautier SV, Monakhov AR, Tsirulnikova OM, Zubenko SI, Sitnikova EV, Umrik DV, et al. Outcomes of liver transplantation in hepatocellular carcinoma: a single-center experience. Annaly khirurgicheskoy gepatologii = Annals of HPB Surgery. 2020;25(2):67–76. (In Russ.). https://doi.org/10.16931/1995-5464.2020267-76

5. Vivarelli M, Cucchetti A, Piscaglia F, La Barba G, Bolondi L, Cavallari A, et al. Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression. Liver Transpl. 2005;11(5):497–503. PMID: 15838913 https://doi.org/10.1002/lt.20391

6. Vivarelli M, Cucchetti A, La Barba G, Ravaioli M, Del Gaudio M, Lauro A, et al. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence. Ann Surg. 2008;248(5):857–862. PMID: 18948815 https://doi.org/10.1097/SLA.0b013e3181896278

7. Vivarelli M, Dazzi A, Zanello M, Cucchetti A, Cescon M, Ravaioli M, et al. Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma. Transplantation. 2010;89(2):227–231. PMID: 20098287 https://doi.org/10.1097/TP.0b013e3181c3c540

8. Rodríguez-Perálvarez M, Tsochatzis E, Naveas MC, Pieri G, García-Caparrós C, O'Beirne J, et al. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma. J Hepatol. 2013;59(6):1193–1199. PMID: 23867318 https://doi.org/10.1016/j.jhep.2013.07.012

9. Rodríguez-Perálvarez M, De la Mata M, Burroughs AK. Liver transplantation: immunosuppression and oncology. Curr Opin Organ Transplant. 2014;19(3):253–260. PMID: 24685671 https://doi.org/10.1097/MOT.0000000000000069

10. Lerut J, Iesari S, Foguenne M, Lai Q. Hepatocellular cancer and recurrence after liver transplantation: what about the impact of immunosuppression? Transl Gastroenterol Hepatol. 2017;2:80. PMID: 29167827 https://doi.org/10.21037/tgh.2017.09.06 eCollection 2017.

11. Ossami Saidy RR, Postel MP, Pflüger MJ, Schoening W, Öllinger R, Gül-Klein S, et al. Minimization of immunosuppressive therapy is associated with improved survival of liver transplant patients with recurrent hepatocellular carcinoma. Cancers (Basel). 2021;13(7):1617. PMID: 33807392 https://doi.org/10.3390/cancers13071617

12. Verna EC, Patel YA, Aggarwal A, Desai AP, Frenette C, Pillai AA, et al. Liver transplantation for hepatocellular carcinoma: management after the transplant. Am J Transplant. 2020;20(2):333-347. PMID: 31710773 https://doi.org/10.1111/ajt.15697